BF-A vs CLX

The Advanced Deterministic Scorecard shows a Piotroski F-Score of 6/9, indicating stable financial health, but the absence of an Altman Z-Score limits distress risk assessment. Despite solid profitability metrics like a 29.44% operating margin and 20.67% ROE, the company faces significant headwinds with negative revenue and earnings growth. Valuation appears stretched relative to intrinsic value models, and insider selling, weak price performance, and declining fundamentals reinforce caution. The stock trades well above the Graham Number of $18.3, suggesting overvaluation absent exceptional growth—contradicted by current contraction trends.

The Clorox Company presents as a classic value trap, characterized by a stable Piotroski F-Score of 5/9 but severely undermined by a massive valuation gap, with a current price of $98.68 far exceeding its growth-based intrinsic value of $42.77. Financial health is concerning due to critical liquidity shortages, evidenced by a Quick Ratio of 0.38 and a Current Ratio of 0.74. Negative year-over-year revenue (-0.80%) and earnings (-16.20%) growth, combined with a 0/100 technical trend, indicate a strong bearish momentum. While the 5.03% dividend is attractive, the 80.52% payout ratio is increasingly risky given the declining earnings trajectory.